As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
34 Analysts have issued a AbbVie forecast:
34 Analysts have issued a AbbVie forecast:
Jun '25 |
+/-
%
|
||
Revenue | 58,328 58,328 |
6%
6%
|
|
Gross Profit | 41,372 41,372 |
13%
13%
|
|
EBITDA | 26,509 26,509 |
8%
8%
|
EBIT (Operating Income) EBIT | 18,239 18,239 |
14%
14%
|
Net Profit | 3,723 3,723 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Head office | United States |
CEO | Robert Michael |
Employees | 55,000 |
Founded | 2011 |
Website | www.abbvie.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.